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Objective: To evaluate rituximab (RTX) in patients with rheumatoid arthritis-associated 
bronchiectasis (RA-BR) and compare 5-year respiratory survival between those treated with 
RTX and tumour necrosis factor inhibitors (TNFi).  
Methods: A retrospective observational cohort study of RA-BR in RTX or TNFi-treated RA 
patients from two UK centres over 10 years. BR was assessed using number of infective 
exacerbation/year. Respiratory survival was measured from therapy initiation to 
discontinuation either due to lung exacerbation or lung-related deaths.   
Results: Of 800 RTX-treated RA patients, 68 had RA-BR (prevalence 8.5%). Post-RTX, new 
BR was diagnosed in 3/735 patients (incidence 0.4%). At 12 months post-Cycle 1 RTX, 21/68 
(31%) patients had fewer exacerbations than the year pre-RTX, 36/68 (53%) remained stable 
and 11/68 (16%) had increased exacerbations. The rates of exacerbation improved after Cycle 
2 and stabilised up to 5 cycles. Of patients who received ≥2 RTX cycles (n=60), increased 
exacerbations occurred in 7/60 (12%) and were associated with low IgG, aspergillosis and 
concurrent alpha-1-antitrypsin deficiency. Overall, 8/68 (11.8%) patients discontinued RTX 
while 15/46 (32.6%) discontinued TNFi due to respiratory causes. The adjusted 5-year 
respiratory survival was better in RTX-treated compared to TNFi-treated RA-BR patients; HR 
0.40 (95% CI 0.17–0.96); p=0.041. 
Conclusion:  The majority of RTX-treated RA-BR patients had stable/improved pulmonary 
symptoms in this long-term follow-up. In isolated cases, worsening of exacerbation had 
definable causes. Rates of discontinuation due to adverse lung outcomes were better for RTX 
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Key Messages: 
1. RTX showed satisfactory safety profile in rheumatoid arthritis-associated 
bronchiectasis. 
2. Most RTX-treated RA-BR patients had either stable or improved exacerbation/year 
over 10-year follow-up.  
3. Fewer patients with RA-BR discontinued RTX due to adverse lung outcomes than 
those on TNFi.  
INTRODUCTION 
Bronchiectasis (BR) is a chronic lung disease characterised by irreversible dilatation and 
thickening of the airways associated with chronic cough, increased sputum production, 
bacterial colonisation and recurrent infections. It is a significant pulmonary morbidity common 
in people with rheumatoid arthritis (RA) that is reported in up to 12% of RA patients [1]. The 
standardised mortality ratios of patients with co-existence of RA and bronchiectasis (RA-BR) 
are 7.3 times higher than the general population, 5 times that of patients with RA alone and 2.4 
times that of patients with other non-cystic fibrosis BR over 5 years [2]. All deaths in the RA-
BR group were due to respiratory infection and/or respiratory failure.  
 
While the treatment of RA has greatly improved over the last 15 years with the introduction of 
biologic disease modifying anti-rheumatic drugs (bDMARDs), the use of these therapies has 
often been restricted in RA-BR due to concerns of infectious complications. Indeed, in a 
retrospective study of 40 patients with RA-BR, the authors reported that both the use of 
bDMARDs i.e. tumour-necrosis factor inhibitors (TNFi) or rituximab (RTX) and sputum 
colonisation by any bacteria increased the odds of infection compared to those treated with 
conventional synthetic DMARDs (csDMARDs) [3].  In addition, the long-term safety profile 
of TNFi in RA from randomised controlled trials and observational studies showed increased 
rates of severe infection in TNFi-treated compared to csDMARDs-treated patients [4, 5]. 
Therefore, a non-TNFi such as RTX is often preferentially used to treat RA-BR patients with 
moderate to severely arthritis.  
 
The rationale for B-cell targeted therapy in RA-BR is supported by the multiple pathogenic 
roles of B-cells including their antibody-dependent function since B-cells are the source of 
rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPAs). A previous study 
also reported that ACPA response to citrullination was more specific in patients with RA-BR 
than those with BR alone [6]. Nevertheless, clinical evidence for the efficacy and safety of 
RTX in the context of BR is scarce. Furthermore, patients with RA-BR are normally excluded 
from formal clinical trials due to comorbidity. Therefore, data from larger longitudinal studies 
are needed.  
 
In order to address the gaps in knowledge and in the absence of a head-to-head trial of RTX 
against TNFi for the treatment of RA-BR, the objectives of this study were to evaluate effect 
of RTX in patients with RA-BR as assessed by number of infective exacerbations, imaging, 
mortality and compare 5-year respiratory survival between patients with RA-BR who were 
treated with RTX and TNFi.  
 
METHODS 
Patients and Design 
All patients with moderate to severe RA who were treated with RTX or TNFi at two different 
centres in the UK; Leeds Teaching Hospitals NHS Trust and Gateshead Hospital NHS 
Foundation Trust between January 2002 and May 2017 were evaluated retrospectively from 
the biologics databases of each institution. From this, a longitudinal cohort study of consecutive 
patients with RA-BR was conducted. Inclusion criteria were adults (≥18 years old), fulfilling 
the revised 1987 American College of Rheumatology for RA [7] and detection of BR by high 
resolution computed tomography (HRCT) [8]. Leeds (West) Research Ethics Committee and 
Gateshead Hospitals Ethical Committee confirmed that ethical approval was not required in 
accordance with the UK National Health Service Research Ethics Committee guidelines 
because all treatment decisions were made prior to evaluation of data. 
 
Treatment Protocol 
For the RTX group, all patients received a first cycle of therapy of 100 mg of 
methylprednisolone and 1000 mg of RTX (MabThera) given intravenously on days 1 and 14. 
Further treatment cycles consisted of the same regimen were repeated on clinical relapse. For 
the TNFi group, all patients were treated with either infliximab (Remicade), etanercept 
(Enbrel), adalimumab (Humira) or certolizumab (Cimzia) as per summary of product 
characteristics for each drug.   
 
Demographics 
Identical data collection methodology were undertaken between the two centres. Age, gender, 
disease duration for RA and BR, seropositivity status i.e. RF and/or ACPA, previous treatment 





Disease activity was assessed using the Disease Activity Score in 28 joints based on C-reactive 
protein (DAS28-CRP) at baseline and every 3 months. Articular response at 6 months was 
assigned according to the criteria of the European League Against Rheumatism (EULAR) [9]. 
 
Infective exacerbation of bronchiectasis  
Medical case notes, rheumatology and respiratory clinic letters, hospital discharge letters and 
electronic health records for all patients with RA-BR treated with RTX or TNFi who attended 
the rheumatology and/or respiratory clinics at both centres were inspected thoroughly for 
infective exacerbation episodes and sputum culture results. Infective exacerbation was defined 
as acute deterioration (usually over several days), with worsening of cough, increased sputum 
volume, viscosity, or purulence and/or systemic upset and requiring new prescriptions for 
antibiotics, which was in line with the British Thoracic Society guideline [8]. These episodes 
were then summarised as number of infective exacerbations/year. Clinical lung response was 
defined as stable or improvement in number of infective exacerbation/year.  
 
HRCT Scoring for Bronchiectasis 
HRCT scans were acquired (when clinically indicated) in RTX-treated patients with worsening 
dyspnoea and/or deterioration in the rate of infective exacerbation using a standardised method 
at the two centres. The scans were scored independently by two radiologists; MD, a chest 
radiologist and  GL, a general radiologist; both who had over 10 years’ experience in reporting 
BR and blinded to clinical information, treatment and the sequence of scans.  
 
The modified Bhalla score [10, 11] was used to evaluate the fourteen HRCT parameters in the 
six lung zones, as detailed in the online supplementary file. The total score for each patient 
was obtained by summing the scores for each morphological change, which were attributed on 
the basis of the severity/extent of the abnormalities; with a maximum total score possible of 
37. Each paired scan (pre- and post-treatment) was then rated as 0 = worsening, 1 = same and 
2 = improving. Any discrepancy was resolved by consensus. 
  
Respiratory Survival 
All causes of deaths and cessation of RTX or TNFi were recorded. Respiratory survival was 
defined as the time from therapy initiation to discontinuation either due to lung exacerbation 
or deaths from respiratory causes.   
 
Laboratory Assessment 
Total serum immunoglobulin titres were measured by nephelometry (in accredited diagnostic 
laboratories) at baseline and at 4-6 months after each cycle of RTX (normal range for IgM: 0.5-
2.0 g/L; IgA: 0.8-4.0 g/L and IgG: 6.0-16.0 g/L). An automated Fluorescent Immuno Enzyme 
Assay (FIEA) ImmunoCAP was used to detect IgG antibodies to Aspergillus.  
 
Peripheral blood B-cell subsets were analysed using highly sensitive flow cytometry (HSFC) 
as previously described in Leeds [12] and conventional flow cytometry at Gateshead at week 
0, 2 and 26 without knowledge of clinical status other than time since RTX. In order to 
standardise B-cells reporting between centres, complete B-cell depletion was defined as counts 
<0.0001 × 106 cells/L. 
 
Statistical Analysis 
Associations between categorical variables were tested by Fisher’s exact. Continuous variables 
were compared using either Student’s T-tests or Mann-Whitney U test depending on data type 
and distribution. For prediction of the initial lung exacerbation, multiple imputation by chained 
equations was used to estimate missing data and twenty multiple imputation sets were used to 
provide stability of results. For multivariable logistic regression analyses, backward 
elimination was used with a p-value of <0.25 associated with the deviance used for exclusion 
from the model. 
 
Survival (measured in weeks and years) was calculated from the date of first RTX infusion or 
TNFi administration to either the date of death, cessation of therapy or the date of data last 
updated (May 2017). The 5-year respiratory survival between the two treatment groups was 
analysed using Cox-regression proportional hazard and adjusted for the relevant confounders.  
All statistical analysis was performed using IBM SPSS Statistics v21.0 (IBM Corp, Armonk, 




Of 800 patients with RA treated with RTX in both centres, 68 patients had RA-BR (i.e. 
prevalence 8.5%) and were included in the analysis. Of these, 48 (71%) were female, mean age 
63 years (standard deviation (SD) 10),  median RA duration 7 years (interquartile range (IQR) 
4-12), median BR duration 6 years (range 1-67) at RTX initiation. Total follow-up: 298.5 
patient-years (PY). Post-RTX, new BR was diagnosed in only 3/735 patients (i.e. incidence 
0.4%).  Of these 3 patients, BR was diagnosed after 1.7 years of exposure and at least two RTX 
cycles.  
Baseline characteristics of RTX-treated and TNFi-treated patients are compared in Table 1. 
Most characteristics were matched between these two cohorts. However, median number of 
infective exacerbations/year in the previous 12 months pre-bDMARDs was higher in those 
treated with RTX than TNFi.  
 
Treatment Characteristics 
213 cycles of RTX were administered to the 68 patients studied. Median (IQR) duration of 
response for cycles 1–3 (C1–3) were 54 (46–68), 50 (40–64) and 52 (46–60) weeks 
respectively. Prior to C1, 22/68 had either inadequate response or intolerance to TNFi (TNF-
IR), of which their first TNFi were infliximab=13, etanercept=6 and adalimumab=3. Of these, 
the reasons for TNF-IR were primary non-response=3, secondary non-response=9, lung 
exacerbation=7 and other adverse events=3. In C1 of RTX, 43/68 (63%) of the patients were 
on concomitant csDMARDs. Of 46 patients in the TNFi-treated group, their first TNFi 
therapies were etanercept=20, infliximab=18, adalimumab=7 and certolizumab=1. Total 
follow-up for this group was 222.2 PY. 
 
Articular Response to RTX  
In C1, there was a significant reduction in DAS-28(CRP); mean (SD) pre-RTX 5.81 (0.76) 
versus 3.50 (1.09) post-RTX, mean difference (SD) at 6 months -2.31 (-1.12) [95% confidence 
interval (CI) -2.68 to -1.94]; p<0.001. EULAR response rates; Good, Moderate and Poor at 6 
months post-RTX were 26/68 (38.2%), 35/68 (51.5%) and 7/68 (10.3%) respectively. 58/68 
(85.3%) had complete B-cell depletion post-RTX.  
 
Of the 7 patients who were C1 non-responders, 4/7 had incomplete B-cell depletion post-RTX. 
6/7 were re-treated at 6 months with subsequent complete B-cell depletion and response in only 
2/6 patients in C2.  
 
EULAR response rates (Good and Moderate) for C2, C3, C4 and C5 were 43/60 (71.7%), 20/24 
(83.3%), 19/21 (90.5%) and 11/12 (91.7%) respectively (Figure 1A).  At the last follow-up, 
5/68 (7.4%) had secondary non-response to RTX and were switched to different bDMARDs; 
tocilizumab (n=3) and abatacept (n=2). 
 
Clinical lung response to RTX in the initial follow-up 
The number of infection episodes reduced from 216 events in 58 RTX-treated RA-BR patients 
(3.18 PY) in the year pre-RTX to 190 in 48 patients (2.79 PY) at 12 months post-C1 RTX.  
At 12 months post-C1 RTX, there was no significant difference in median number of infective 
exacerbations/year versus the year pre-RTX; p=0.105. Median (IQR) number of infective 
exacerbations/year 12 months pre-RTX and 12 months post-C1 RTX were 3 (1-4) and 3 (0-4) 
respectively. At 12 months post-C1 RTX, 21/68 (31%) patients had fewer exacerbations 
compared to the year pre-RTX; 36/68 (53%) remained stable and 11/68 (16%) had increased 
exacerbations. 
 
Timing of infective exacerbation since first cycle RTX  
The cumulative proportions of patients who had their first infective exacerbation within 6 
weeks, 12 weeks, 26 weeks and 52 weeks from C1 RTX were 15/48 (31.3%), 24/48 (50%), 
46/48 (95.8%)  and 48/48 (100%) respectively. This is illustrated in Figure 1B. 
 
Factors predicting increased lung exacerbation at 12 months post-RTX 
In imputed multivariable analysis, the presence of pseudomonas colonisation in sputum was 
associated with increased risk of lung exacerbation at 12 months post-RTX, OR 7.23 (95% CI 
1.28-40.80), p=0.025. Older age was associated with reduced risk, OR 0.44 (95% CI 0.21-0.90) 
per 10 years of age, p=0.025 (Table 2).  
 
Clinical lung response to RTX in long-term follow-up 
Overall, median number of infective exacerbations/year improved after C2 RTX and remained 
stable up to 5 cycles (Figure 1C). At the end of the follow-up, 17/68 (25%) patients 
discontinued RTX. Reasons for discontinuation were i) deaths = 9, of which 5/68 (7%) were 
from respiratory causes; ii) lung exacerbation or safety issues = 3 and iii) secondary inefficacy 
= 5.  
 
Factors associated with lung worsening following initial stability to RTX 
60/68 patients received at least two RTX cycles. Of these, 7/60 (12%) had worsening number 
of infective exacerbations/year following C2 RTX. The median (range) RTX cycles where lung 
worsening occurred was 4 (3-8).  
 
The causes contributing to lung worsening were investigated and identified. These were 
secondary hypogammaglobulinaemia (IgG<6 g/L) = 5 (of which, one required 
immunoglobulin replacement), aspergillosis = 3 and concurrent alpha-1-anti-trypsin deficiency 
= 1. Aspergillosis was diagnosed based on a combination of typical characteristics on HRCT, 
positive ELISA test for Aspergillus antibody from broncho-alveolar lavage and strongly 
positive IgG antibody to Aspergillus (>39.9 mg/L) [13]. Figure 2 depicted HRCT scans of a 
patient who developed aspergillosis at 5 years post-RTX. Of 3 patients with concurrent 
aspergillosis, 1 discontinued RTX despite treatment with voriconazole and subsequently 
underwent lobectomy.  
 
Imaging lung response to RTX 
Pre- and post-HRCT scans were performed in 12 RA-BR patients with worsening dyspnoea 
and/or deterioration in the rate of infective exacerbation. The median (IQR) duration between 
the two scan time-points was 5 (1.4-6.5) years. There was no statistical difference in the 
modified Bhalla score between pre-RTX and post-RTX scans, median (IQR) 14 (8-17) and 15 
(11-17) respectively; p=0.064. Overall, 7/12 (58%) had unchanged images while 5/12 (42%) 
had worsening imaging changes post-RTX.  
 
Comparison of 5-year respiratory survival between RTX and TNFi-treated RA-BR 
In the RTX-treated RA-BR group, 8/68 (11.8%) patients discontinued RTX due to respiratory 
causes (lung infection-related deaths = 5; lung exacerbation = 3). While in the TNFi-treated 
RA-BR group, 15/46 (32.6%) patients discontinued TNFi due to respiratory causes (lung 
infection-related deaths = 2; lung exacerbation = 13 including one patient treated with 
etanercept who later developed aspergillosis) (Table 3). The death rates due respiratory causes 
were nearly similar in the RTX-treated than the TNFi-treated groups; (5/68) 7.4% and (2/46) 
4.3% respectively. Distribution of TNFi in those who discontinued therapy due to respiratory 
causes was etanercept = 6, infliximab = 6, adalimumab = 2 and certolizumab = 1.  
 
After inspecting for various demographic variables including BR disease duration and number 
of exacerbation/per year, only centre effect emerged as a confounder. There was a significantly 
better 5-year respiratory survival in the RTX-treated RA-BR compared to TNFi-treated RA-
BR patients; hazard ratio (HR) 0.40 (95% CI 0.17 – 0.96); p=0.041 after adjusting for age, 




This is the first reported experience to date of patients with RA-BR treated with RTX or TNFi 
from a multicentre cohort study. The majority of patients with RA-BR (as assessed by number 
of infective exacerbation/year and survival) remained stable or improved during RTX therapy 
over 10 years follow-up.   
 
A handful of case series have reported on the development or worsening of BR following 
treatment with RTX [14, 15]. These data need to be interpreted with caution due to publication 
bias, lack of generalisation and inability to establish cause-effect relationship. By reviewing 
records of every patient who received RTX to capture every BR patient in a systematic way, 
our data ameliorate the difficulties in the interpretation of these case reports. The data show 
that RTX appears to be generally safe and the incidence of BR after RTX therapy was low i.e. 
0.4%.  
 
In the 12 months post-RTX, 84% of patients had either stable or improved number of 
exacerbations compared to the year prior to RTX initiation. This rate is better than the 68% 
reported on the use of RTX in another lung comorbidity i.e. RA-related interstitial lung disease 
[16]. However, 16% of the patients experienced temporary worsening of infective exacerbation 
of their BR. A factor predicting this exacerbation was pseudomonas colonisation in sputum.  
This was despite 7/8 of patients with pseudomonas colonisation being treated with either 
prophylactic macrolide antibiotics or inhaled colomycin at RTX baseline. This highlighted the 
need to improve on strategies to eradicate pseudomonas aeruginosa in the management of BR. 
Pseudomonas colonisation was also identified as a risk factor of exacerbation in cystic fibrosis 
[17] and non-autoimmune related BR [18]. In contrast to other studies of non-cystic fibrosis 
BR [19, 20], older age reduced the risk of initial exacerbation following RTX in this study. 
One explanation could be that this group of patients had slower progressive disease compared 
to younger patients.  
 
The long-term clinical lung response to RTX was also supported by the unchanged HRCT 
scores in over half of the symptomatic patients, in whom a deterioration in HRCT scores would 
have been expected. Nevertheless, isolated cases of worsening of exacerbations following 
initial stability were observed. These had definable causes including secondary 
hypogammaglobulinaemia, aspergillosis and concurrent alpha-1-antitrypsin deficiency. Low 
IgG level is an independent predictor of infection during RTX therapy [21, 22]. Thus, 
immunoglobulin should be monitored at RTX initiation and before each retreatment and RA-
BR patients with low IgG should be considered for other therapies than RTX from the 
perspective of safety. In line with the British Thoracic guidelines, RA patients being treated 
with immunosuppressive therapies who present with increasing productive cough and 
breathlessness should be investigated using HRCT and other secondary causes of BR including 
aspergillosis and alpha-1-antitrypsin deficiency [23] sought. It is unclear whether repeated 
treatment with RTX increase the risk of aspergillosis in RA-BR since previous case series only 
reported in RTX-treated haematological malignancy patients who also underwent 
haematopoietic stem cell transplant [24] or combination therapy with other chemotherapies 
[25].  
 
In the absence of head-to-head trials of RTX and TNFi, the 5-year respiratory survival and 
mortality of the patients in these two cohorts were compared. It is worth noting that median 
number of exacerbations/year in the RTX was higher than the TNFi groups. This was due to 
channelling bias and tendency of the clinicians to treat patients with the most severe lung 
morbidity with RTX, thus resulting in an increase in reports of adverse events in the RTX-
treated RA-BR cohort. Despite this, our data showed that the 5-year respiratory survival was 
significantly better in the RTX compared to the TNFi groups. In the TNFi group, there was no 
difference between the use of monoclonal antibodies and receptor protein with regards to 
respiratory survival.  
 
This study has some limitations. First, the design was retrospective, hence could lead to recall 
bias by the patients. However, a standard proforma was used in the clinics to document the 
number of exacerbations/year as well as infection episodes were thoroughly searched for 
during data collection. Second, pulmonary function testing was not routinely undertaken at 
both centres and there was a varied availability of pre- and post-RTX HRCT scans for every 
patient. Nevertheless, number of exacerbation/year is a valid measure to assess clinical efficacy 
in BR and has been widely used as a primary endpoint in clinical trials [26, 27]. Lastly,  only 
12/68 (18%) of the patients in this cohort were treated with prophylactic antibiotics during 
RTX therapy despite over half i.e. 35/68 (59%) having ≥3 exacerbations/year as advocated by 
the European [28] and British Thoracic Society [23] guidelines. Thus, this could contribute to 
higher rate of infection episodes in this RTX-treated RA-BR cohort.  
 
To conclude, since most patients with RA-BR had stable or improved lung exacerbations 
during RTX therapy as well as better 5-year respiratory survival against a matched TNFi 
cohort, our findings offer reassurance that RTX is an acceptable treatment choice for RA-BR 
patients with severe arthritis, who require treatment with a biologic. These data also support a 
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Table 1: Baseline characteristics of the 114 patients with RA-BR included in this study 








Age, years: mean (SD) 62.9 (9.9) 63.3 (10.1) 62.4 (9.8) 
Female: n (%) 81 (71.1) 48 (70.6) 33 (71.7) 
Sero-positivity [RF and/or anti-CCP 
antibody positive]: n (%) 
110 (96.5) 68 (100) 42 (91.3) 
RA Disease duration, years: median 
(IQR) 
6.5 (3.3-11.5) 7.2 (4.2-12.0) 4.7 (2.2-9.0) 
*BR Disease duration: median (IQR) 5.0 (1.4-10.7) 6.4 (2.1-12.0) 4.8 (0.9-8.5) 
No. of infective exacerbation/year in 
the previous 12 months pre-
bDMARDs: median (IQR) 
2.0 (0-3) 3.0 (1-4) 0 (0-2) 
Biologic naïve: n (%) 92 (81) 46 (68) 46 (100) 
No. of previous TNFi: median (range) 0 (0-1) 0 (0-3) 0 (0) 
Concomitant anti-malarial only: n (%) 6 (5.3) 6 (8.8) 0 (0) 
Concomitant csDMARDs: n (%) 
     Methotrexate 
     Leflunomide 
     Sulfasalazine 
     Azathioprine 



















Concomitant prednisolone: n (%) 38 (33.3) 23 (33.8) 15 (32.6) 
Daily prednisolone dose, mg: median 
(IQR) 
0 (0-5) 0 (0-5) 0 (0-5) 
Ever smoked: n (%) 54 (47.4) 29 (42.6) 25 (54.3) 
DAS-28(CRP) score: mean (SD) 5.9 (0.7) 5.9 (0.8) 5.6 (0.6) 
 
*BR disease duration was analysed in patients who BR were diagnosed prior to therapy with 
bDMARDs  
bDMARDs: Biologic disease modifying agent anti-rheumatic drugs, BR: Bronchiectasis, CCP: 
Cyclic citrullinated peptide, csDMARDs: Conventional synthetic disease modifying agent anti-
rheumatic drugs, DAS-28 (CRP): Disease activity score in 28 joints based on C-reactive 
protein, IQR: interquartile range, RA: rheumatoid arthritis, RF: Rheumatoid factor, RTX: 
Rituximab, SD: standard deviation,  TNFi: Tumour necrosis factor inhibitor 
Table 2: Predictors of lung exacerbation at 12 months post-RTX 
 
 Stable or 
Improving 
Lung Disease 
N = 57 
Lung 
Exacerbation  
N = 11 
Univariable OR 




(95% CI), P-value 
(with multiple 
imputation) 
Age, years: mean 
(SD) 
64.2 (9.3) 58.4 (12.7) 0.58 (0.31-1.08) 
Per 10 years of 
age, P = 0.085 
0.44 (0.21-0.90) 
Per 10 years of 




2.9 (0.7-8.7) 2.8 (0.6-5.4) 0.96 (0.88-1.06) 
Per year, P = 0.454 
 
- 
No. of infective 
exacerbation/year in 
the previous 12 
months pre-RTX: 
median (IQR) 
2 (1-4) 4 (2-6) 1.16 (0.93-1.44), 
P = 0.186 
1.17 (0.92-1.49), 
P = 0.197 
Ever smoked: n (%) 23 (40.4) 6 (54.6) 1.78 (0.48-6.51), 
P = 0.387 
 
2.71 (0.59-12.35), 
P = 0.198 
Pseudomonas 
colonisation in 
sputum: n (%) 
4 (7.0) 4 (36.4) 7.57 (1.54-37.29), 
P = 0.013 
7.23 (1.28-40.80), 
P = 0.025 
Concomitant 
prednisolone, n (%) 
19 (33.3) 4 (36.4) 1.14 (0.30-4.39) 




csDMARDs: n (%) 








P = 0.231 
- 
 
BR: Bronchiectasis, csDMARDs: Conventional synthetic disease modifying anti-rheumatic 
drugs, IQR: interquartile range,  RTX: Rituximab, SD: standard deviation, TNFi: Tumour 
necrosis factor inhibitor 
  
Table 3: Reasons for bDMARDs discontinuation in RA-BR patients 
 
Causes Rituximab (N = 68) TNF-inhibitor (N = 46) 
Deaths, n (%) 
     Lung infection-related, n (%) 
     Cerebrovascular accident, n (%)  









Lung exacerbation, n (%) 3 (4.4) 13 (28.3) 
Patients who stopped therapy due to 
mortality/respiratory causes, n (%) 
8 (11.8) 15 (32.6) 
Primary inefficacy, n (%) 0 3 (6.5) 
Secondary inefficacy, n (%) 5 (7.4) 9 (19.6) 
Other adverse events, n (%) 0 3 (6.5) 
Total patients who discontinued 
bDMARDs therapies, n (%) 
17 (25) 30 (65) 
 
bDMARDs: Biologic disease modifying agent anti-rheumatic drugs   
Figure 1: Efficacy and safety of RTX in RA-BR. A) High EULAR (Good and moderate) 
response rates were observed over 5 RTX cycles. B) There was no difference in the number of 
infective exacerbation/year in the year pre-RTX versus 12 months post-RTX. These rates had 
improved and were stable up to 5 RTX cycles. The bars represent median and the error bars 
denote 95% confidence interval. C) Survival graph of timing of the first infection episode 
following RTX therapy. D) Comparison of 5-year respiratory survival between RTX-treated 
and TNFi-treated RA-BR patients. Grey line in the graph represents RTX while black line 
denotes TNFi. 
 
Figure 2: HRCT image of a RTX-treated RA-BR patient who developed aspergillosis 
after RTX therapy. A and B) Orange arrows denote bronchial wall thickening and signet-ring 
signs. Blue arrows denote cystic formation towards the lung peripheries. Red arrow denotes 
progression of the cysts containing air fluid crescents suggestive of pulmonary mycetoma 
formation. 
